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Letter to the Editor
Full Resistance and Decreased Susceptibility to Carbapenems in
IMP-13-Producing Pseudomonas aeruginosa
Isolates from an Outbreak
Of 23 ceftazidime-resistant Pseudomonas aeruginosa isolates
with simultaneous decreased susceptibility to carbapenems re-
covered from inpatients at Hospital Eva Peron, Provincia de
Buenos Aires, Argentina, from December 2004 to December
of 2005, 18 were positive by a double-disk phenotypic screening
of metallo--lactamases (MBLs) using EDTA (1 mol) (6).
Decreased susceptibility was defined as to refer to isolates with
MICs of 2 to 8 g/ml or inhibition zones of 16 to 21 mm,
categorized as susceptible or intermediate according CLSI
breakpoints, but which clearly differed from fully susceptible
isolates.
All of these isolates could be categorized as susceptible to
piperacillin, piperacillin-tazobactam, and colistin. Thirteen of
18 isolates were susceptible to amikacin, while 5/18 were in-
termediate. They were all resistant to ceftazidime, cefepime,
gentamicin, and ciprofloxacin. From them, 14 displayed de-
creased susceptibility to imipenem (IPM) and meropenem
(MEM) (inhibition zone range, 16 to 21 mm), while 4 (con-
secutive) isolates were considered fully resistant to both (Table
1). Independently of their categorization, pulsed-field gel elec-
trophoresis (PFGE) profiles using 20 U/plug SpeI nuclease
(NEB) were identical after standard resolution (4).
These 18 isolates were positive when screened for the class
1 integrase gene and rendered a unique fragment correspond-
ing to the variable region of class 1 integrons, in which imp-13
was the first cassette, followed downstream by an aminoglyco-
side-modifying enzyme-coding gene, aacA4 (AM931299), 99%
identical to that already deposited for Tn5051 (5, 9).
Because a difference in final carbapenem resistance could be
due to different mechanisms, including differential -lactamase
content and expression, crude extracts were examined after
analytical isoelectrofocusing, detecting enzymatic activity with

























1 65/male 11/26/04 — ICU ABS AF SAM, TZP, CIP,
IPM
12/14/04 20 (S) 4 (S) 18 (S) 4 (S) CST Died
2 69/female 12/15//04 AH, SK ICU EVS BL/CAT VAN, SXT,
AMK
12/31/04 21 (S) 2 (S) 17 (S) 4 (S) CST Died
3 60/male 12/30/04 AMI, AH ICU Sepsis BL SAM, GEN 1/11/05 20 (S) 2 (S) 16 (S) 4 (S) CIP, SAM,
GEN
Died
4 57/male 3/25/05 SCZ, SK,
COL
ICU VAP BAL CRO, CIP, TZP,
IPM, SXT
4/7/05 21 (S) 2 (S) 21 (S) 4 (S) SXT, IPM Died
6 56/female 2/28/05 DM, CRF GW SSTI, OS BO Unknown 5/16/05 21 (S) 2 (S) 17 (S) 4 (S) Unknown Favorable
5 31/male 5/11/05 — ICU VAP BAL CAZ, VAN 5/18/05 20 (S) 2 (S) 16 (S) 2 (S) PIP, AMK Died
7 86/female 5/10/05 DM ICU CAI CAT CRO, CAZ,
AMK, VAN
5/26/05 21 (S) 2 (S) 17 (S) 4 (S) IPM Died
8 22/male 5/28/05 SK ICU VAP BAL 6/3/05 21 (S) 2 (S) 21 (S) 4 (S) CIP, AMK Favorable
9 49/male 5/27/05 COPD CRF ICU VAP BAL SAM, CIP 7/9/05 18 (S) 2 (S) 19 (S) 2 (S) IPM, CST Died
10 42/male 7/05/05 — ICU VAP BAL CRO, CLI 7/9/05 21 (S) 2 (S) 20 (S) 4 (S) IPM, CST Died
11 67/male 7/08/05 AH ICU VAP BAL CIP, AMK 7/15/05 21 (S) 2 (S) 19 (S) 4 (S) IPM Favorable
12 79/male 7/15/05 DV, HF ICU VAP BAL SAM, CIP 7/23/05 18 (S) 4 (S) 17 (S) 8 (I) IPM, CST Died
13 27/female 8/14/05 — ICU VAP BAL TZP, VAN, CAZ,
IPM, SAM
12/10/05 6 (R) 32 (R) 6 (R) 128 (R) TZP Favorable
14 31/male 12/5/05 — GW/S SSTI ST IPM, VAN 12/11/05 6 (R) 32 (R) 6 (R) 128 (R) IPM, VAN,
CST
Died
15 33/male 12/19/05 — GW SSTI ST CFZ, GEN, ERY 12/21/05 7 (R) 32 (R) 6 (R) 128 (R) IPM, AMK Favorable
16 36/female 12/19/05 DM, CRF GW CAI BO/CAT IPM, VAN 12/30/05 6 (R) 32 (R) 6 (R) 128 (R) AMK, CST Died
17 33/male 12/19/05 — GW/S SSTI ST CFZ, GEN 1/2/06 20 (S) 2 (S) 20 (S) 2 (S) IPM, AMK Favorable
18 56/male 12/9/05 VL ICU PSP AF IPM, VAN,
SXT, RIF
1/6/06 21 (S) 2 (S) 21 (S) 2 (S) IPM, VAN Favorable
a Results for carbapenem-resistant isolates are shown in boldface. Screening for MBL was performed using disks containing 1 mol EDTA 15 mm from disks
containing imipenem, meropenem, and ceftazidime.
b —, no underlying conditions; AH, arterial hypertension; SK, smoking; AMI, acute myocardial infarction; SCZ, schizophrenia; COL, colectomy; DM, diabetes
mellitus; CRF, chronic renal failure; COPD, chronic obstructive pulmonary disease; DV, diverticulosis; HF, heart failure; VL, vesicular litiasis.
c ICU, intensive care unit; GW, general ward; GW/S, general ward/surgery.
d ABS, abdominal sepsis; EVS, endovascular sepsis; VAP, ventilator-associated pneumonia; SSTI, skin and soft tissue infection; OS, osteomyelitis, CAI, catheter-
associated infection; PSP, postsurgical peritonitis.
e AF, abdominal fluid; BL, blood; CAT, catheter; BAL, bronchoalveolar lavage; BO, bone; ST, soft tissue.
f SAM, ampicillin-sulbactam; TZP, piperacillin-tazobactam; CIP, ciprofloxacin; IPM, imipenem; VAN, vancomycin; SXT, trimethoprim-sulfamethoxazole; AMK,
amikacin; GEN, gentamicin; CRO, ceftriaxone; CAZ, ceftazidime; CLI, clindamycin; CFZ, cefazolin; ERY, erythromycin; RIF, rifampin; CST, colistin.















an iodometry-based overlay system (8); no differences could be
seen between both groups of isolates, and no suggestion for
any other acquired -lactamase or overexpression of the chro-
mosomal AmpC could be inferred. No significant difference
could be found between both groups of isolates concerning
spectrophotometric enzymatic activity (EA), expressed as “to-
tal” -lactamase activity (using cephalothin [CEF] as a
reporter), and carbapenemase activity (using imipenem as re-
porter). EA for cephalothin (EACEF) (U/mg protein) for IPM-
resistant isolates and IPM-susceptible isolates were (1.7 
0.3)  107 and (2.2  0.7)  107, respectively. EA for IPM
(EAIPM) (U/mg protein) were (2.7  0.6)  10
07 and (4.2 
2.0)  107 for resistant and susceptible isolates, respectively.
Hydrolysis of imipenem relative to cephalothin (AEIPM/AECEF)
was 1.5 versus 1.8 in the resistant and susceptible groups, respec-
tively, suggesting there is no difference in the level of expression
of carbapenemases between IPM-resistant and IPM-susceptible
isolates.
Resistant isolates also lacked a 46-kDa band in outer mem-
brane protein (OMP) profiles (assumed as OprD) (1, 2, 7).
In vitro analysis for the presence of a high-level resistance
subpopulation in two carbapenem-susceptible (IMP-13 pro-
ducing) isolates (isolates 3 and 7) showed that both MEM and
IPM at 16 g/ml could select fully resistant subpopulations at
frequencies ranging from 2  108 to 1.6  107 from over-
night cultures when cultured on antibiotic-containing agar
plates. Independently of the selecting antibiotic, they displayed
resistance to both carbapenems. Not a single colony could be
obtained by single-step selection from reference strains
(ATCC 9027) or clinical isolates without IMP-13 at this con-
centration.
Mortality among patients with IMP-13-producing (IPM-sus-
ceptible) P. aeruginosa infections treated with IPM alone or in
combination was 5/8. As this analysis is retrospective, whether
subpopulations of fully resistant microorganisms that resulted
in treatment failures may have also emerged in those patients
(as actually occurs in vitro) cannot be ruled out.
We suggest MBL producers with MICs in the susceptible
range should be clearly reported (categorized) differently, in-
dicating the discordance between susceptibility and the pres-
ence of a resistance marker, even if their resistance levels do
not anticipate therapeutic failure. This categorization would
help to redefine the current knowledge on the epidemiological
analysis comparing the evolution of patients infected by micro-
organisms classified as susceptible to carbapenems, but which
prove to be IMP producers. Furthermore, this approach may
contribute by providing data for discussing if, eventually, the
presence of this associated resistance mechanism should mod-
ify current CLSI breakpoints (3).
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